source
- Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M dealDimerix has bought an acute kidney injury drug from Mission Therapeutics, paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready asset.Fierce Biotech · 13d ago↗ source
- Biotronik Neuro snaps up spinal cord stimulation portfolio from Soin Neuroscience for next-gen pain projectBiotronik Neuro has acquired a portfolio of spinal cord stimulation patents from the Ohio-based medical device company Soin Neuroscience as the pair look to create “a next-generation spinal cord st…Fierce Biotech · 13d ago↗ source
- Mirador unveils part of pipeline with drug from Kira to rival TavneosMirador Therapeutics, the secretive immune disease biotech with more than $650 million in VC funding, is finally revealing a piece of its pipeline. The San Diego biotech said Thursday it reached a…